FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562345461> ?p ?o ?g. }

• W2562345461 abstract "Abstract Abstract 2629 Acute myeloid leukemia (AML) relapse is often associated with a poor outcome, in particular in the post allogneic stem cell transplantation ( Allo-SCT) setting. Therapeutic options in patients relapsing early after SCT are further limited partially due to the risk of increased toxicity. In patients who did not develop graft versus host disease ( GVHD), reduction or cessation of immunosuppression therapy may result in the achievement of a graft versus leukemia (GvL) effect. However, this is usually only beneficial in patients with a low disease burden. Gemtuzumab Ozogamicin (GO) was introduced into therapy of CD33 positive AML patients as a targeted therapy with a relatively safe extra-medullary toxicity profile. Although withdrawn from the USA market by the FDA, recent studies have shown efficacy of combining GO with chemotherapy in newly diagnosed AML patients. We hypothesized that in patients with AML relapsing early after an Allo-SCT, combination of GO with single agent chemotherapy will result in disease control for a sufficient amount of time to allow a trial of GvL induction. Therapy consisted of high dose ARA-C (1 gr/m2) for 4 days followed by one dose of GO, 9 mg/m2 on day 5. To decrease hematopoietic toxicity, therapy was supported by donor stem cells, when available. Responding patients which did not develop GVHD, where eligible for cell mediasted immunotherapy with a donor lymphocyte infusion(DLI) or a second Allo-SCT. 16 patients (F=10, M=6), median age 52 years (range 26–63) are included in this analysis. The majority (14/16) of patients were previously transplanted for a high risk AML (secondary AML-6, unfavorable cytogenetics-5, FLT3-ITD-3); disease status at SCT were CR1 (n=8), CR2 (n=4), untreated 1st relapse (n=1) and at diagnosis (n=1, MDS with excess of blasts). AML relapse occurred at a median of 104 days (range 15–403) after SCT. ARA-C/GO therapy was supported with donor stem cells in 8/16 patients and was relatively well tolerated. One patient died in aplasia in day +2 due to sepsis resulting in overall 6% induction mortality. Five patients developed veno occlusive disease of the liver ( VOD )(36% of evaluable patients); all were mild and resolved with symptomatic care. Responses were achieved in 8/15 (53%) evaluable patients, all CR/CRp. Four patients in CR/CRp received further therapy with DLI (n=3) or Allo SCT from a different donor (n=1), and 2 non-responding patients received a second Allo-SCT after second line salvage chemotherapy. At long follow up, 1 patient (6%) is alive in and continuous remission (1040 days after therapy). In patients surviving induction, death occurred due to relapse (n=10) or severe GVHD (n=5). Median EFS and OS were 55 and 133 days, respectively in the entire cohort. Median EFS was longer in responding patients (156 vs. 16 days, p<0.0001), while median OS was not significantly different in these 2 patients cohorts (204 vs. 33 days, p=0.2). ARA-C/GO combination is a valid option for salvage therapy in AML patients relapsing after an Allo-SCT and is well tolerated. Although responses are usually of a short duration, they may allow immunogenic manipulation in the absence of an already established significant GVHD, and may result in a long term disease control in a minority of patients. Disclosures: No relevant conflicts of interest to declare." @default.
• W2562345461 created "2017-01-06" @default.
• W2562345461 creator A5009040323 @default.
• W2562345461 creator A5011217358 @default.
• W2562345461 creator A5020301140 @default.
• W2562345461 creator A5020369229 @default.
• W2562345461 creator A5040016022 @default.
• W2562345461 creator A5045152818 @default.
• W2562345461 creator A5058925624 @default.
• W2562345461 creator A5081737366 @default.
• W2562345461 date "2012-11-16" @default.
• W2562345461 modified "2023-09-27" @default.
• W2562345461 title "Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses." @default.
• W2562345461 doi "https://doi.org/10.1182/blood.v120.21.2629.2629" @default.
• W2562345461 hasPublicationYear "2012" @default.
• W2562345461 type Work @default.
• W2562345461 sameAs 2562345461 @default.
• W2562345461 citedByCount "0" @default.
• W2562345461 crossrefType "journal-article" @default.
• W2562345461 hasAuthorship W2562345461A5009040323 @default.
• W2562345461 hasAuthorship W2562345461A5011217358 @default.
• W2562345461 hasAuthorship W2562345461A5020301140 @default.
• W2562345461 hasAuthorship W2562345461A5020369229 @default.
• W2562345461 hasAuthorship W2562345461A5040016022 @default.
• W2562345461 hasAuthorship W2562345461A5045152818 @default.
• W2562345461 hasAuthorship W2562345461A5058925624 @default.
• W2562345461 hasAuthorship W2562345461A5081737366 @default.
• W2562345461 hasConcept C10205521 @default.
• W2562345461 hasConcept C126322002 @default.
• W2562345461 hasConcept C141071460 @default.
• W2562345461 hasConcept C143998085 @default.
• W2562345461 hasConcept C176290653 @default.
• W2562345461 hasConcept C2776694085 @default.
• W2562345461 hasConcept C2777408962 @default.
• W2562345461 hasConcept C2778245361 @default.
• W2562345461 hasConcept C2778623314 @default.
• W2562345461 hasConcept C2778729363 @default.
• W2562345461 hasConcept C2779695342 @default.
• W2562345461 hasConcept C28328180 @default.
• W2562345461 hasConcept C2911091166 @default.
• W2562345461 hasConcept C29730261 @default.
• W2562345461 hasConcept C54355233 @default.
• W2562345461 hasConcept C71924100 @default.
• W2562345461 hasConcept C86803240 @default.
• W2562345461 hasConcept C90924648 @default.
• W2562345461 hasConceptScore W2562345461C10205521 @default.
• W2562345461 hasConceptScore W2562345461C126322002 @default.
• W2562345461 hasConceptScore W2562345461C141071460 @default.
• W2562345461 hasConceptScore W2562345461C143998085 @default.
• W2562345461 hasConceptScore W2562345461C176290653 @default.
• W2562345461 hasConceptScore W2562345461C2776694085 @default.
• W2562345461 hasConceptScore W2562345461C2777408962 @default.
• W2562345461 hasConceptScore W2562345461C2778245361 @default.
• W2562345461 hasConceptScore W2562345461C2778623314 @default.
• W2562345461 hasConceptScore W2562345461C2778729363 @default.
• W2562345461 hasConceptScore W2562345461C2779695342 @default.
• W2562345461 hasConceptScore W2562345461C28328180 @default.
• W2562345461 hasConceptScore W2562345461C2911091166 @default.
• W2562345461 hasConceptScore W2562345461C29730261 @default.
• W2562345461 hasConceptScore W2562345461C54355233 @default.
• W2562345461 hasConceptScore W2562345461C71924100 @default.
• W2562345461 hasConceptScore W2562345461C86803240 @default.
• W2562345461 hasConceptScore W2562345461C90924648 @default.
• W2562345461 hasLocation W25623454611 @default.
• W2562345461 hasOpenAccess W2562345461 @default.
• W2562345461 hasPrimaryLocation W25623454611 @default.
• W2562345461 hasRelatedWork W2001421019 @default.
• W2562345461 hasRelatedWork W2020984688 @default.
• W2562345461 hasRelatedWork W2341077074 @default.
• W2562345461 hasRelatedWork W2533486448 @default.
• W2562345461 hasRelatedWork W2559605832 @default.
• W2562345461 hasRelatedWork W2559858932 @default.
• W2562345461 hasRelatedWork W2562266793 @default.
• W2562345461 hasRelatedWork W2563377881 @default.
• W2562345461 hasRelatedWork W2566578687 @default.
• W2562345461 hasRelatedWork W2567528160 @default.
• W2562345461 hasRelatedWork W2573444275 @default.
• W2562345461 hasRelatedWork W2578657405 @default.
• W2562345461 hasRelatedWork W2581220283 @default.
• W2562345461 hasRelatedWork W2581801010 @default.
• W2562345461 hasRelatedWork W2590040607 @default.
• W2562345461 hasRelatedWork W2597968974 @default.
• W2562345461 hasRelatedWork W2781565767 @default.
• W2562345461 hasRelatedWork W2979733543 @default.
• W2562345461 hasRelatedWork W2979838055 @default.
• W2562345461 hasRelatedWork W2979941814 @default.
• W2562345461 isParatext "false" @default.
• W2562345461 isRetracted "false" @default.
• W2562345461 magId "2562345461" @default.
• W2562345461 workType "article" @default.